| 替吉奥联合紫杉醇治疗晚期胃癌的疗效分析 |
| 投稿时间：2014-09-14 修订日期：2014-11-05 点此下载全文 |
| 引用本文：姜敏,曾越灿,吴荣.替吉奥联合紫杉醇治疗晚期胃癌的疗效分析[J].医学研究杂志,2015,44(5):52-56 |
| DOI：
10.11969/j.issn.1673-548X.2015.05.014 |
| 摘要点击次数: 1949 |
| 全文下载次数: 1007 |
|
| 基金项目:国家自然科学基金资助项目(81201803) |
|
| 中文摘要:目的 观察分析紫杉醇联合替吉奥治疗晚期胃癌的疗效和安全性。方法 选取笔者医院经病理确诊的61 例进展期胃癌患者,随机分为治疗组及对照组。治疗组32例:紫杉醇175mg/m2,静脉滴注3h,第1天;替吉奥胶囊每天80mg/m2,分早晚两次,餐后口服,第1~14天;对照组29例:奥沙利铂130mg/m2,静脉滴注,第1天;替吉奥胶囊用法同治疗组。以上两方案均以3周为1个周期。结果 61例均纳入分析,其中没有完全缓解病例,疾病控制率是84.4%、79.3%, 中位PFS分别是5.6个月、4.9个月;中位OS 分别是13.1个月、13.6个月。两组间差异无统计学意义。全组不良反应较轻,多为Ⅰ~Ⅱ度,主要为骨髓抑制、消化道反应、乏力等。其中对照组外周神经毒性反应的发生率高于治疗组。结论 紫杉醇联合替吉奥3 周方案治疗晚期胃癌治疗效果良好,不良反应可以耐受。 |
| 中文关键词:紫杉醇 替吉奥 胃癌 |
| |
| Clinical Efficacy of Tegafur Gimeracil Oteracil Potassium Capsule Plus Paclitaxel in Treatment of Advanced Gastric Cancer |
|
|
| Abstract:Objective To assess and analyze the efficacy and safety of Tegafur Gimeracil Oteracil Potassium capsule plus paclitaxel against advanced gastric cancer. Methods Totally 61 patients with advanced gastric cancer were randomly divided into two groups: the treatment group(32 cases) and the control group(29 cases). Patients in the treatment group were treated with Tegafur Gimeracil Oteracil Potassium capsule (80mg/m2) orally, for 14 days continuously, and paclitaxel (175mg/m2) on the first day.Patients in the control group were applied with oxaliplatin (130mg/m2) on the first day, and the same dose of Tegafur Gimeracil Oteracil Potassium capsule. The two groups both used three weeks as a cycle. Results All 61 patients were included for analysis. No complete response was observed. The overall disease control rate was 84.4%, 79.3%, respectively. The median progression free survival time was respectively 5.6 months and 4.9 months. The median survival time was respectively 13.1 months and 13.6 months. There's no significant difference between the two groups. The adverse effects were mostly tolerable, big part of which grade 1/2, mainly included hematological adverse effects, digestive system adverse effect, fatigue and so on. The incidence of neurotoxic effect of control group was higher than treatment group. Conclusion Tri-weekly paclitaxel combined Tegafur Gimeracil Oteracil Potassium Capsule is safe and effective in patients with advanced gastric cancer, which is worthy further study. |
| keywords:Paclitaxel Tegafur Gimeracil Oteracil Potassium capsule Gastric cancer |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
